Considering the positive findings regarding the amelioration of cognitive function in animal models that were treated with NLRP3 inflammasome inhibitors, as well as the first attempts to undertake clinical trials with the afore-mentioned drugs, this area of research sheds a light on the development of new potential approaches to AD treatment. Here, NLRP3 is linked to Alzheimer disease.